TISI heads into its Q1 2026 earnings release with the stock down 12.5% on the week — and a cluster of board-level purchases still sitting underwater.
The week's most telling tension sits between director buying and the price action. Three independent directors built positions in late March at prices between $14.44 and $16.31, committing roughly $289,000 in net new capital over a 10-day window. The lead independent director, Anthony Horton, put in $144,400 alone. The stock has since slipped below those entry levels, printing $15.10 on Tuesday. That puts the board's collective March purchases in the red — a backdrop that makes Wednesday's earnings call the most important near-term test for their conviction.
The short side offers little in the way of aggression. Short interest sits at just 0.42% of the free float — barely a rounding error. It ticked up roughly 6% over the past week, but that followed a 22% collapse over the prior month. The borrow market is equally relaxed: cost to borrow has drifted down to 0.55%, its lowest level in two months, and availability is wide. Days to cover run at about four days on the most recent FINRA filing. None of this signals a crowded short or meaningful squeeze risk.
The ownership picture adds another layer. Corre Partners Management holds 35% of shares and has been a consistent buyer through late 2025. Barclays and 22NW hold another 10% combined. With 34 total institutional holders and a relatively thin float, this is a tightly held name — which means the 12.5% weekly drop is amplified by thin liquidity rather than any broad institutional exodus. Vanguard and BlackRock added modestly to their positions in the most recent reporting period, both through Q1 2026.
The ORTEX short score has eased slightly to 30.6 from a recent high above 31, consistent with positions trimming ahead of the print. The factor score picture is middling — a sector rank of 50 and a dividend score of 28 — offering no particular edge in either direction. Valuation data is stale and unreliable for this note.
What arrived after market close Tuesday told the first part of the story: Q1 adjusted EPS came in at -$2.76, an improvement from -$3.31 a year ago, on revenue of $215.1 million versus $198.7 million. Full-year 2026 guidance was set at $920–$945 million in sales. At the Q4 2025 print in March, the stock fell 8.5% the next day before recovering to a 1.6% gain over five sessions. The Q1 2026 earnings call is scheduled for Wednesday morning — and whether improved revenue momentum against a still-negative EPS trajectory is enough to hold the $15 level is now the only question that matters.
See the live data behind this article on ORTEX.
Open TISI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
